Feb 22, 2015
Cadwalader is representing Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), a leading U.S. specialty pharmaceutical company, which today announced a definitive agreement to be acquired by Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) for $158.00 per share, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the Salix and Valeant boards of directors and is expected to close in the second quarter of 2015, subject to customary closing conditions and regulatory approval.
Cadwalader has advised Salix in connection with various governance, litigation and transactional matters, including its terminated combination with Cosmo Technologies.
The Cadwalader team is led by partner and Chair of the Corporate Group, Christopher Cox, and includes Corporate partners Gregory Patti, Jr., William Mills and Ira Schacter, Corporate special counsel Andrew Alin, and Corporate associates Anita Wong and Alexandra Cotter, in New York; Antitrust partners Rick Rule and Andrew Forman in Washington, DC.; Tax partner Linda Swartz and special counsel Edward Wei in New York; Intellectual Property partner Dorothy Auth in New York; and Finance partner Jeff Nagle in Charlotte.
About Salix Pharmaceuticals, Ltd.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license or acquire late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and commercialize them through Salix’s 500-member specialty sales force.
Scott Cammarn, Mark Chorazak, Jonathan Watkins,Chris Gavin, Joseph Beach, Peter Morreale
Richard Brand, Stephen Fraidin, Jonathan Watkins, James Fee
Michele Maman, Thomas Curtin, Anthony De Leo, Donny Ariel
Jeffrey Rotblat will discuss "Accumulation/Aggregation/Alternative Exit Strategies" at this event.